Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma 2Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 7Fluorouracil 7pembrolizumab 5Leucovorin 5Trastuzumab 4Radiation 4Paclitaxel 4Capecitabine 4tislelizumab 3Taxes 3Specimen Handling 3Nivolumab 3Carboplatin 3zanidatamab 2ulixertinib 2trastuzumab biosimilar HLX02 2Surgical Procedures, Operative 2Radiotherapy 2Pemetrexed 2PF-05280014 2Ontruzant 2Ogivri 2Irinotecan 2Exercise 2Docetaxel 2Cisplatin 2CT-P6 2zolbetuximab 1zimberelimab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × zolbetuximab × 30 days × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡